Ten years ago, it would have seemed unthinkable that an independent, non-profit organization with no statutory power whatsoever could influence the pricing behavior of the multi-billion-dollar US pharmaceutical sector. Yet that is what the Institute for Clinical and Economic Review has achieved. Since its foundation in 2006, the organization has steadily expanded its authority and credibility among health care stakeholders. And now that it has industry’s ear, it is seeking to shape more than just drug prices.
“Absolutely, we want to influence policy” around drug pricing and access, said Steven Pearson, ICER’s founder and president and the...